相关实验视频
Updated: Jul 2, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
常规改善了通过AMPK/SREBP1通路的糖尿病NAFLD的脂质代谢功能障碍
Yadi Liu1, Zhongyan Sun1, Ruixue Dong2
1Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, Macao, PR China.
素是一种类黄胺,通过减少肝脂肪,炎症和氧化应激,有效治疗糖尿病非酒精性脂肪性肝病 (NAFLD). 它通过激活AMPK通路来起作用,这表明它作为这种疾病的新疗法具有潜力.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 糖尿病肝损伤经常与非酒精性脂肪性肝病 (NAFLD) 相关,这是最常见的慢性肝病.
- 鲁是一种来自氨酸的生物黄,具有已知的降糖,胰岛素调节和抗炎性质.
- 鲁丁对糖尿病NAFLD的治疗效果仍然在很大程度上未被探索.
研究的目的:
- 为了研究鲁丁对糖尿病NAFLD的保护作用.
- 阐明Rutin在治疗糖尿病NAFLD的基础药理机制.
主要方法:
- 已建立的糖尿病NAFLD模型使用db/db小鼠和体外细胞培养 (HeLa, HepG2) 暴露于油酸,d-葡萄糖和棕酸.
- 通过Oil Red O染色和BODIPY 493/503评估脂质积累,量化胆固醇和甘油三,并测量炎症和氧化应激标志物.
- 利用RNA测序和16SrRNA分析来探索机制,重点关注AMPK途径和脂质代谢基因;用于验证的是化合物C抑制剂.
主要成果:
- 在糖尿病NAFLD的体外和体外模型中,鲁丁显著降低了脂质积累.
- 常规减轻了炎症和氧化应激,并改善了肠道微生物群的失调 (例如,Firmicutes/Bacteroidetes比率).
- RNA-seq显示,鲁的改善作用涉及AMPK/SREBP1通路,调节关键的脂质合成蛋白.
结论:
- 鲁丁通过激活AMPK通路,显示出对糖尿病NAFLD的显著保护作用.
- 鲁丁可以作为一个有前途的治疗剂或成分,用于管理糖尿病NAFLD.
更多相关视频
07:03Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
08:20Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...